Rigel Pharmaceuticals Inc (RIGL): Long-Term Debt
$52.50M
As of 2025-12-31
+9.5%
3-year compound annual growth
+21.3%
5-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $52.50M | -12.5% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $60.00M | 0.0% | 2025-03-04, Balance as of period end |
| 2023-12-31 | $60.00M | +50.0% | 2024-03-05, Balance as of period end |
| 2022-12-31 | $40.00M | +100.0% | 2023-03-07, Balance as of period end |
| 2021-12-31 | $20.00M | 0.0% | 2022-03-01, Balance as of period end |
| 2020-12-31 | $20.00M | +100.0% | 2021-03-02, Balance as of period end |
| 2019-12-31 | $10.00M | n/a | 2020-02-27, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $52.50M | -12.5% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $202.83M | +34.5% |
| Standard Biotools Inc. (LAB) | 2024-12-31 | $299.0K | -99.5% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $47.21M | n/a |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $108.96M | +1.6% |
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $74.10M | n/a |
| Harrow, Inc. (HROW) | 2025-12-31 | $250.00M | -4.8% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $220.34M | -5.1% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $48.25M | +24.7% |
Compare RIGL, ARDX, LAB, NUVB side by side · Screen every company in Pharmaceutical Preparations ↗